SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-057648
Filing Date
2023-12-14
Accepted
2023-12-14 16:30:44
Documents
13
Period of Report
2023-12-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20016590_8k.htm   iXBRL 8-K 30056
2 EXHIBIT 10.1 ef20016590_ex10-1.htm EX-10.1 48800
  Complete submission text file 0001140361-23-057648.txt   229351

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA erna-20231208.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20231208_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20231208_pre.xml EX-101.PRE 16044
7 EXTRACTED XBRL INSTANCE DOCUMENT ef20016590_8k_htm.xml XML 4233
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 231487449
SIC: 2834 Pharmaceutical Preparations